Robert Langreth Bloomberg
- All
- News
-
Alzheimer's Progression Slowed By Drug In Major Trial
Eisai Co. and partner Biogen Inc. said their Alzheimer's drug significantly slowed the disease, making it the first medicine to clearly blunt theprogression of the most common type of dementia in a definitive, large-scale trial.
-
Enhertu Sharply Improves Survival In Breast Cancer Patients: Report
A drug from AstraZeneca Plc and Daiichi Sankyo Co. extended the lives of patients with an advanced form of breast cancer by about six months in a late-stage trial that may widen the population of people who can benefit from the treatment.
-
After Getting Covid Shot, These People Showed Super-Antibodies
As Covid-19 began spreading in early 2020, one of Linfa Wang's first ideas was to test the blood of people who'd survived a previous coronavirus outbreak.
-
A Booster In 100 Days To Beat Omicron: The New Challenge
At a plant nestled along a highway 20 miles north of Boston, hundreds of Pfizer Inc. workers are gearing up to produce millions of doses of a new vaccine that looks more and more like the next phase of fighting Covid-19.
-
Omicron Scare: Pfizer Says Third Dose Key To Fight Spread
Pfizer Inc. and BioNTech SE said initial lab studies show a third dose of their Covid-19 vaccine may be needed to neutralize the omicron variant, results that will accelerate booster-shot drives around the world and may lead to use of new strain-spec
-
Mix-And-Match Vaccines Have Big Benefit, Shows New US Study
Mixing Covid vaccines produces as much or more antibodies as using the same shot as a booster, according to preliminary results of a widely awaited US government-sponsored trial.
-
Covid Protection Wanes Months After Second Shot, Booster Needed: Study
Immunity provided by the Covid-19 vaccine from partners Pfizer Inc. and BioNTech SE weakens significantly within months, with men having less protection than women, according to research that supports the use of booster doses.
-
As US Health Body Debates Booster Dose, Spotlight On Israeli Study
A third dose of the Pfizer Inc.-BioNTech SE Covid vaccine can dramatically reduce rates of Covid-related illness in people 60 and older, according to data from a short-term study in Israel.
-
Moderna Says Those Vaccinated Earlier Had Higher Rate Of Infections In Study
Moderna Inc. said that a new analysis of the late-stage clinical trial of its Covid-19 vaccine found a higher rate of breakthrough cases in people who got shots early in the study.
-
One Vaccine Makes More Antibodies Than Another. Does It Matter?
Ten months ago, the results of large clinical trials appeared almost too good to be true: Two messenger RNA vaccines reduced symptomatic Covid-19 cases by more than 90% in almost every group that got them.
-
US Regulator Likely To Clear 3rd Shot For Those With Weak Immune Systems
U.S. drug regulators are set to clear a third dose of Covid vaccines for people with weak immune systems as a new study showed the benefits of an extra shot in transplant patients.
-
What 'Very Real Fourth Wave' Caused By Delta Means For US
A surge in Covid-19 cases across the U.S. brought on by the fast-spreading delta variant is increasing pressure on U.S. drug regulators to fully approve Pfizer Inc.'s vaccine, the first one to apply for full licensure in the U.S.
-
J&J Shot Performs Poorly Against Delta Variant
Johnson & Johnson's single-dose Covid vaccine produced relatively low levels of antibodies against delta variant in a study, raising questions about how well the shot will hold up against the strain that accounts for the vast majority of US cases.
-
The Big Vaccine Update: Pfizer Wants Clearance For Third "Booster" Shot
Pfizer Inc. plans to request U.S. emergency authorization in August for a third booster dose of its Covid-19 vaccine, based on early data showing that it can sharply increase immune protection against the coronavirus.
-
Moderna Says Its Covid Shot Produces Antibodies Against Delta Variant
Moderna Inc. said its vaccine produced protective antibodies against the delta variant spreading in the U.S. and many other parts of the world.
-
Alzheimer's Progression Slowed By Drug In Major Trial
Eisai Co. and partner Biogen Inc. said their Alzheimer's drug significantly slowed the disease, making it the first medicine to clearly blunt theprogression of the most common type of dementia in a definitive, large-scale trial.
-
Enhertu Sharply Improves Survival In Breast Cancer Patients: Report
A drug from AstraZeneca Plc and Daiichi Sankyo Co. extended the lives of patients with an advanced form of breast cancer by about six months in a late-stage trial that may widen the population of people who can benefit from the treatment.
-
After Getting Covid Shot, These People Showed Super-Antibodies
As Covid-19 began spreading in early 2020, one of Linfa Wang's first ideas was to test the blood of people who'd survived a previous coronavirus outbreak.
-
A Booster In 100 Days To Beat Omicron: The New Challenge
At a plant nestled along a highway 20 miles north of Boston, hundreds of Pfizer Inc. workers are gearing up to produce millions of doses of a new vaccine that looks more and more like the next phase of fighting Covid-19.
-
Omicron Scare: Pfizer Says Third Dose Key To Fight Spread
Pfizer Inc. and BioNTech SE said initial lab studies show a third dose of their Covid-19 vaccine may be needed to neutralize the omicron variant, results that will accelerate booster-shot drives around the world and may lead to use of new strain-spec
-
Mix-And-Match Vaccines Have Big Benefit, Shows New US Study
Mixing Covid vaccines produces as much or more antibodies as using the same shot as a booster, according to preliminary results of a widely awaited US government-sponsored trial.
-
Covid Protection Wanes Months After Second Shot, Booster Needed: Study
Immunity provided by the Covid-19 vaccine from partners Pfizer Inc. and BioNTech SE weakens significantly within months, with men having less protection than women, according to research that supports the use of booster doses.
-
As US Health Body Debates Booster Dose, Spotlight On Israeli Study
A third dose of the Pfizer Inc.-BioNTech SE Covid vaccine can dramatically reduce rates of Covid-related illness in people 60 and older, according to data from a short-term study in Israel.
-
Moderna Says Those Vaccinated Earlier Had Higher Rate Of Infections In Study
Moderna Inc. said that a new analysis of the late-stage clinical trial of its Covid-19 vaccine found a higher rate of breakthrough cases in people who got shots early in the study.
-
One Vaccine Makes More Antibodies Than Another. Does It Matter?
Ten months ago, the results of large clinical trials appeared almost too good to be true: Two messenger RNA vaccines reduced symptomatic Covid-19 cases by more than 90% in almost every group that got them.
-
US Regulator Likely To Clear 3rd Shot For Those With Weak Immune Systems
U.S. drug regulators are set to clear a third dose of Covid vaccines for people with weak immune systems as a new study showed the benefits of an extra shot in transplant patients.
-
What 'Very Real Fourth Wave' Caused By Delta Means For US
A surge in Covid-19 cases across the U.S. brought on by the fast-spreading delta variant is increasing pressure on U.S. drug regulators to fully approve Pfizer Inc.'s vaccine, the first one to apply for full licensure in the U.S.
-
J&J Shot Performs Poorly Against Delta Variant
Johnson & Johnson's single-dose Covid vaccine produced relatively low levels of antibodies against delta variant in a study, raising questions about how well the shot will hold up against the strain that accounts for the vast majority of US cases.
-
The Big Vaccine Update: Pfizer Wants Clearance For Third "Booster" Shot
Pfizer Inc. plans to request U.S. emergency authorization in August for a third booster dose of its Covid-19 vaccine, based on early data showing that it can sharply increase immune protection against the coronavirus.
-
Moderna Says Its Covid Shot Produces Antibodies Against Delta Variant
Moderna Inc. said its vaccine produced protective antibodies against the delta variant spreading in the U.S. and many other parts of the world.
